07 Jan 2001

Dayamineral jarabe - España

Updated: 07 Jan 2001

Dayamineral jarabe jarabe 125 ml

Profilaxis y tratamiento de estados carenciales de vitaminas y minerales: Embarazo, lactancia, astenia, crecimiento, etc.

Dayamineral jarabe Description, Presentation and Dosage

Dayamineral jarabe Description

Dayamineral jarabe Drug Class Description

Polivitaminicos con minerales

Dayamineral jarabe Drug Description

JARABE

Dayamineral jarabe Presentation

Dayamineral jarabe Presentation

Lactantes: 1/2 cucharadita/día. Niños: 1 cucharadita/día. Adultos: 2 cucharaditas/día.

Dayamineral jarabe Manufacturer

ABBOTT LABORATORIES

Related Learning Zones

Hyperammonaemia Knowledge Centre

Hyperammonaemia Knowledge Centre

The Hyperammonaemia Knowledge Centre has been developed to raise awareness of this rare yet potentially deadly condition. Using this resource, healthcare professionals are encouraged to recognise the signs and symptoms of hyperammonaemia and begin the correct treatment immediately.

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Dayamineral jarabe Dosage

Dayamineral jarabe Precautions, Reactions and Contraindications

Dayamineral jarabe Special Precautions

Related Drugs - Gastroenterologia

Back to top